Predictive Power of Multiplex Serum Biomarkers in Breast Cancer: A Comprehensive ROC Curve Analysis
ROC curve analysis of biomarkers in BC
DOI:
https://doi.org/10.29409/zvqcs091Keywords:
AKT, Breast Cancer, Mammaglobin, Mucin, ResistinAbstract
Introduction: Breast carcinoma is one of the most prevalent cancers in women, with its progression influenced by a complex interplay of genetic and environmental factors. This study aimed to investigate the association between resistin, mammaglobin, MUC1, CA15-3, CEA, and AKT pathway activation in breast cancer development. Methods: A cross-sectional study design was performed in Iraq/ Medical City at Baghdad/ Oncology Teaching Hospital. All samples (105 samples of blood) were classified into 3 groups; each one contains 35 samples. Results: A serological analysis was conducted using ELISA to measure serum levels of key biomarkers. Malignant samples exhibited elevated concentrations of mammaglobin (mean: 3.74 ng/ml), resistin (mean: 4.195 ng/ml), CA15-3 (mean: 36.15 ng/ml), CEA (mean: 41.983 ng/ml), mucin1 (mean: 33.45 ng/ml), and AKT (mean: 3.174 ng/ml). Conclusion: The findings suggest that a combined assessment of these tumor markers could enhance the prognosis, diagnosis, detection, and monitoring of breast cancer. Notably, CEA and MUC1 demonstrated superior sensitivity and specificity, positioning them as highly reliable biomarkers for clinical application.
References
1. Shakir N. Evaluating the Level of Some Antioxidants and C-Reactive Activators Protein in a Sample of Iraqi Women with Breast Cancer: Level of Antioxidants in Women with Breast Cancer. Iraqi Journal of Cancer and Medical Genetics. 2024 Jun 1;17(1):51-6.
2. Diao S, Wu X, Zhang X, Hao Y, Xu B, Li X, Tian L, Miao Y, Zhao X, Ye F, Li J. Obesity-related proteins score as a potential marker of breast cancer risk. Scientific Reports. 2021 Apr 15;11(1):8230.
3. Shoeib SM, Elsharaby RM, Elakshar S, El-Gohary RM, Zamzam YA. RETN gene polymorphisms and serum resistin levels in patients with breast cancer. Egyptian Journal of Cancer and Biomedical Research. 2024 Dec 1;8(4):1-0.
4. Borri F, Granaglia A. Pathology of triple negative breast cancer. In Seminars in cancer biology 2021 Jul 1 (Vol. 72, pp. 136-145). Academic Press.
5. Ricks-Santi LJ, Fredenburg K, Rajaei M, Esnakula A, Naab T, McDonald JT, Kanaan Y. Characterization of GATA3 and Mammaglobin in breast tumors from African American Women. Research Square. 2023 Jan 25:rs-3.
6. Oktaviyanti IK, Ali DS, Awadh SA, Opulencia MJ, Yusupov S, Dias R, Alsaikhan F, Mohammed MM, Sharma H, Mustafa YF, Saleh MM. RETRACTED ARTICLE: Recent advances on applications of immunosensing systems based on nanomaterials for CA15-3 breast cancer biomarker detection. Analytical and Bioanalytical Chemistry. 2023 Jan;415(2):367-.
7. Zhang Y, Zhao J, Wang Y, Cai W, Zhang X, Li K, Liu W, Zhao Y, Kang H. Changes of tumor markers in patients with breast cancer during postoperative adjuvant chemotherapy. Disease Markers. 2022;2022(1):7739777.
8. Jarallah SA, Al-Fartusie FS, Zgeer DS. Evaluating the level of trace elements in Iraqi women Genetics with early-stage breast cancer. Iraqi Journal of Cancer & Medical Genetics. 2024 Jan 1;17(1).
9. Dong C, Wu J, Chen Y, Nie J, Chen C. Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer. Frontiers in pharmacology. 2021 Mar 15;12:628690.
10. Fatima M, Baba KS, Sreedevi NN, Kumar JP, Raju GS, Uppin SG, Bhaskar MV, Khan SA, Iyyapu KM, Noorjahan M. Evaluation of Serum Mammaglobin as an Alternative Biomarker in the Diagnosis of Breast Tumors. Journal of Laboratory Physicians. 2023 Mar;15(01):020-4.
11. Patel A, Shah S. Noninvasive biomarkers: Emerging trends in early detection of breast cancer. Breast cancer: From bench to personalized medicine. 2022 May 15:125-43.
12. Gallucci G, Massa E, Funes CC, Tozzini R, Ghersevich S. The combination of mammaglobin A and TWIST-1 increases detection of circulating tumor cells in breast cancer. Jornal Brasileiro de Patologia e Medicina Laboratorial. 2021 May 14;57:e2102021.
13. Li C, Zhang T. Human mammaglobin: a specific marker for breast cancer prognosis. J buon. 2016 Jan 1;21(1):35-41.
14. Muñoz-Palomeque A, Guerrero-Ramirez MA, Rubio-Chavez LA, Rosales-Gomez RC, Lopez-Cardona MG, Barajas-Avila VH, Delgadillo-Barrera A, Canton-Romero JC, Montoya-Fuentes H, Garcia-Cobian TA, Gutierrez-Rubio SA. Association of RETN and CAP1 SNPs, expression and serum resistin levels with breast cancer in Mexican women. Genetic testing and molecular biomarkers. 2018 Apr 1;22(4):209-17.
15. Deb A, Deshmukh B, Ramteke P, Bhati FK, Bhat MK. Resistin: A journey from metabolism to cancer. Translational oncology. 2021 Oct 1;14(10):101178.
16. Assiri AM, Kamel HF. Evaluation of diagnostic and predictive value of serum adipokines: Leptin, resistin and visfatin in postmenopausal breast cancer. Obesity research & clinical practice. 2016 Jul 1;10(4):442-53.
17. Parafiniuk K, Skiba W, Pawłowska A, Suszczyk D, Maciejczyk A, Wertel I. The role of the adipokine resistin in the pathogenesis and progression of epithelial ovarian cancer. Biomedicines. 2022 Apr 16;10(4):920.
18. Du F, Yu L, Wu Y, Wang S, Yao J, Zheng X, Xie S, Zhang S, Lu X, Liu Y, Chen W. miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4. Cell Death & Disease. 2019 Dec 4;10(12):922.
19. Li X, Dai D, Chen B, Tang H, Xie X, Wei W. Clinicopathological and Prognostic Significance of Cancer Antigen 15‐3 and Carcinoembryonic Antigen in Breast Cancer: A Meta‐Analysis including 12,993 Patients. Disease markers. 2018;2018(1):9863092.
20. Huebner H, Häberle L, Müller V, Schrader I, Lorenz R, Forstbauer H, Fink V, Schochter F, Bekes I, Mahner S. MUC1 (CA27. 29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. Cancers 2022, 14, 1721 [Internet]. 2022
21. Song Y, Zhu X, Lin Z, Luo L, Wen D. The potential value of serum chemerin in patients with breast cancer. Scientific Reports. 2021 Mar 22;11(1):6564.
22. Al Zobair AA, Hayawi MA, Al Obeidy BF. Reliability of CA15-3 Tumor Marker in Monitoring Therapeutic Response in Different Molecular Subtypes of Metastatic Breast Cancer. Middle East Journal of Cancer. 2022 Jul 1;13(3):438-48.
23. Jing X, Liang H, Hao C, Yang X, Cui X. Overexpression of MUC1 predicts poor prognosis in patients with breast cancer. Oncology reports. 2019 Feb 1;41(2):801-10.
24. Hinz N, Jücker M. Distinct functions of AKT isoforms in breast cancer: a comprehensive review. Cell Communication and Signaling. 2019 Dec;17:1-29.
25. Kaboli PJ, Imani S, Jomhori M, Ling KH. Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy. American journal of cancer research. 2021 Oct 15;11(10):5155.
26. Nan J, Li J, Li X, Guo G, Wen X, Tian Y. Preoperative serum carcinoembryonic antigen as a marker for predicting the outcome of three cancers. Biomarkers in cancer. 2017 Feb 8;9:1179299X17690142.
27. Dai D, Chen B, Tang H, Wang B, Zhao Z, Xie X, Wei W. Nomograms for predicting the prognostic value of pre-therapeutic CA15-3 and CEA serum levels in TNBC patients. PloS one. 2016 Aug 25;11(8):e0161902.
28. Zajkowska M, Gacuta E, Kozłowska S, Lubowicka E, Głażewska EK, Chrostek L, Szmitkowski M, Pawłowski P, Zbucka-Krętowska M, Ławicki S. Diagnostic power of VEGF, MMP-9 and TIMP-1 in patients with breast cancer. A multivariate statistical analysis with ROC curve. Advances in medical sciences. 2019 Mar 1;64(1):1-8.
29. Mahmoudian M, Razmara E, Mahmud Hussen B, Simiyari M, Lotfizadeh N, Motaghed H, Khazraei Monfared A, Montazeri M, Babashah S. Identification of a six‐microRNA signature as a potential diagnostic biomarker in breast cancer tissues. Journal of clinical laboratory analysis. 2021 Nov;35(11):e24010.
30. Sahan KA, Aziz IH, Dawood SN, Al Qazzaz H. The role of resistin gene polymorphism in Iraqi breast cancer patients. Biomedicine. 2022 Dec 31;42(6):1296-300.
31. Sahan KA, Aziz IH, Dawood SN, Abdul Razzaq SS. The effect of genetic polymorphism of resistin gene among Iraqi breast cancer women. Iraqi journal of biotechnology. 2023 Oct22(1), 1-7.
32. Shakir N. Evaluating the Level of Some Antioxidants and C-Reactive Activators Protein in a Sample of Iraqi Women with Breast Cancer: Level of Antioxidants in Women with Breast Cancer. Iraqi Journal of Cancer and Medical Genetics. 2024 Jun 1;17(1):51-6.
Additional Files
Received
Revised
Accepted
Published
Data Availability Statement
The data supporting the findings of this study are available from the corresponding author upon reasonable request.
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Cancer and Medical Genetics
This work is licensed under a Creative Commons Attribution 4.0 International License.
